Experienced in Hairy Cell Leukemia (HCL)

Dr. Jennifer R. Eads

Oncology
Penn Medicine
Abramson Cancer Center Radnor
145 King Of Prussia Road, Floor 2, Suite 200 North, 
Radnor, PA 
On Staff At
Accepting New Patients
Offers Telehealth
Experienced in Hairy Cell Leukemia (HCL)
Penn Medicine
Abramson Cancer Center Radnor
145 King Of Prussia Road, Floor 2, Suite 200 North, 
Radnor, PA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Jennifer Eads is an Oncologist in Radnor, Pennsylvania. Dr. Eads is rated as an Experienced provider by MediFind in the treatment of Hairy Cell Leukemia (HCL). Her top areas of expertise are Neuroendocrine Tumor, Stomach Cancer, Gastrointestinal Stromal Tumor, and Colorectal Cancer. Dr. Eads is currently accepting new patients.

Her clinical research consists of co-authoring 37 peer reviewed articles and participating in 17 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has participated in 2 clinical trials in the study of Hairy Cell Leukemia (HCL).

Graduate Institution
Tufts University School Of Medicine
Residency
University Hospitals Case Medical Center
Specialties
Oncology
Licenses
Internal Medicine in PA
Board Certifications
Internal Medicine, 2012
Medical Oncology, 2012
Fellowships
University Hospitals Case Medical Center
Hospital Affiliations
Hospital Of Univ Of Pennsylvania
Chester County Hospital
Pennsylvania Hospital
Penn Presbyterian Medical Center
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Avalon Health Care
  • MEDICARE PDP
Cigna
  • EPO
  • HMO
  • PPO
Clover Health
  • INSURANCE PLAN
  • MEDICARE MAPD
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
Geisinger
  • HMO
  • POS
  • PPO
Health Partners Plans
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
Highmark
  • EPO
  • HMO
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Oscar
  • EPO
  • HMO
  • PPO
PA Health and Wellness
  • HMO
  • MANAGED MEDICAID PLAN
Provider Partners Health Plan
  • MEDICARE SNP
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
UPMC
  • EPO
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 13 Less Insurance Carriers -

Locations

Abramson Cancer Center Radnor
145 King Of Prussia Road, Floor 2, Suite 200 North, Radnor, PA 19087
Call: 215-615-5858
Other Locations
Abramson Cancer Center Perelman 2nd Floor West
3400 Civic Center Boulevard, West Pavilion, 2nd Floor, Philadelphia, PA 19104

Additional Areas of Focus

Dr. Eads has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Esophageal Cancer
Pancreatic Cancer

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

15 Clinical Trials

A Phase II/III Study of Peri-Operative Nivolumab and Ipilimumab in Patients With Locoregional Esophageal and Gastroesophageal Junction Adenocarcinoma
A Phase II/III Study of Peri-Operative Nivolumab and Ipilimumab in Patients With Locoregional Esophageal and Gastroesophageal Junction Adenocarcinoma
Enrollment Status: Suspended
Publish Date: December 17, 2025
Intervention Type: Biological, Drug, Procedure, Radiation
Study Drugs: Carboplatin, Ipilimumab, Nivolumab, Paclitaxel
Study Phase: Phase 2/Phase 3
A Multi-part, Phase 1, Multi-center, Open-label Study of DKN-01 as a Monotherapy or in Combination With Paclitaxel or Pembrolizumab in Patients With Relapsed or Refractory Esophagogastric Malignancies
A Multi-part, Phase 1, Multi-center, Open-label Study of DKN-01 as a Monotherapy or in Combination With Paclitaxel or Pembrolizumab in Patients With Relapsed or Refractory Esophagogastric Malignancies
Enrollment Status: Completed
Publish Date: August 03, 2025
Intervention Type: Drug
Study Phase: Phase 1
A Dose Escalation and Cohort Expansion Study of DKN-01 in Combination With Gemcitabine and Cisplatin in Patients With Advanced Carcinoma Primary to the Intra- or Extra-hepatic Biliary System or Gallbladder
A Dose Escalation and Cohort Expansion Study of DKN-01 in Combination With Gemcitabine and Cisplatin in Patients With Advanced Carcinoma Primary to the Intra- or Extra-hepatic Biliary System or Gallbladder
Enrollment Status: Completed
Publish Date: August 03, 2025
Intervention Type: Drug
Study Phase: Phase 1
An Open-Label Phase Ib/II Study of Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors
An Open-Label Phase Ib/II Study of Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors
Enrollment Status: Terminated
Publish Date: May 08, 2025
Intervention Type: Drug
Study Drug: Surufatinib+Tislelizumab
Study Phase: Phase 1/Phase 2
Randomized Phase II Study of Cisplatin and Etoposide Versus Temozolomide and Capecitabine in Patients With Advanced G3 Non-small Cell Gastroenteropancreatic Neuroendocrine Carcinomas
Randomized Phase II Study of Cisplatin and Etoposide Versus Temozolomide and Capecitabine in Patients With Advanced G3 Non-small Cell Gastroenteropancreatic Neuroendocrine Carcinomas
Enrollment Status: Active_not_recruiting
Publish Date: March 18, 2025
Intervention Type: Drug, Other
Study Drugs: Capecitabine, Carboplatin, Cisplatin, Etoposide, Temozolomide
Study Phase: Phase 2
A Randomized, Double-blind, Placebo-controlled, Active Comparator Phase 2/3 Study of Tucatinib in Combination With Trastuzumab, Ramucirumab, and Paclitaxel in Subjects With Previously Treated, Locally-advanced Unresectable or Metastatic HER2+ Gastric or Gastroesophageal Junction Adenocarcinoma (GEC)
A Randomized, Double-blind, Placebo-controlled, Active Comparator Phase 2/3 Study of Tucatinib in Combination With Trastuzumab, Ramucirumab, and Paclitaxel in Subjects With Previously Treated, Locally-advanced Unresectable or Metastatic HER2+ Gastric or Gastroesophageal Junction Adenocarcinoma (GEC)
Enrollment Status: Completed
Publish Date: January 22, 2025
Intervention Type: Drug, Other
Study Drugs: Tucatinib, Trastuzumab, Ramucirumab, Paclitaxel
Study Phase: Phase 2/Phase 3
Phase I/II Study of CB-839 and Capecitabine in Patients With Advanced Solid Tumors and Fluoropyrimidine Resistant PIK3CA Mutant Colorectal Cancer
Phase I/II Study of CB-839 and Capecitabine in Patients With Advanced Solid Tumors and Fluoropyrimidine Resistant PIK3CA Mutant Colorectal Cancer
Enrollment Status: Completed
Publish Date: December 19, 2024
Intervention Type: Drug
Study Drugs: CB-839, Capecitabine
Study Phase: Phase 1/Phase 2
Phase 2 Study of Telomelysin (OBP-301) in Combination With Pembrolizumab in Esophagogastric Adenocarcinoma
Phase 2 Study of Telomelysin (OBP-301) in Combination With Pembrolizumab in Esophagogastric Adenocarcinoma
Enrollment Status: Completed
Publish Date: June 25, 2024
Intervention Type: Drug
Study Drug: Telomelysin
Study Phase: Phase 2
A Phase I, Open-label, Multiple-ascending Dose Trial to Investigate the Safety, Tolerability, PK, Biological and Clinical Activity of MSB0011359C in Subjects With Metastatic or Locally Advanced Solid Tumors and Expansion to Selected Indications
A Phase I, Open-label, Multiple-ascending Dose Trial to Investigate the Safety, Tolerability, PK, Biological and Clinical Activity of MSB0011359C in Subjects With Metastatic or Locally Advanced Solid Tumors and Expansion to Selected Indications
Enrollment Status: Completed
Publish Date: May 03, 2024
Intervention Type: Drug
Study Phase: Phase 1
A Phase I and Randomized Phase II Study of Nab-Paclitaxel/Gemcitabine With or Without AZD1775 for Treatment of Metastatic Adenocarcinoma of the Pancreas
A Phase I and Randomized Phase II Study of Nab-Paclitaxel/Gemcitabine With or Without AZD1775 for Treatment of Metastatic Adenocarcinoma of the Pancreas
Enrollment Status: Completed
Publish Date: April 25, 2023
Intervention Type: Drug
Study Drugs: Adavosertib, Gemcitabine hydrochloride, Nab-paclitaxel
Study Phase: Phase 1/Phase 2
Phase II Trial of Abemaciclib and Nivolumab for Subjects With Hepatocellular Carcinoma
Phase II Trial of Abemaciclib and Nivolumab for Subjects With Hepatocellular Carcinoma
Enrollment Status: Terminated
Publish Date: December 14, 2022
Intervention Type: Drug
Study Drugs: Abemaciclib, Nivolumab
Study Phase: Phase 2
A Multi-Center Randomized Phase II Study of Nivolumab in Combination With Gemcitabine/Cisplatin or Ipilimumab as First Line Therapy for Patients With Advanced Unresectable Biliary Tract Cancer [CA209-9FC]
A Multi-Center Randomized Phase II Study of Nivolumab in Combination With Gemcitabine/Cisplatin or Ipilimumab as First Line Therapy for Patients With Advanced Unresectable Biliary Tract Cancer [CA209-9FC]
Enrollment Status: Completed
Publish Date: October 28, 2022
Intervention Type: Drug
Study Drugs: Gemcitabine, Cisplatin, Ipilimumab, Nivolumab
Study Phase: Phase 2
A Randomized Phase II Study of Perioperative mFOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel as Therapy for Resectable Pancreatic Adenocarcinoma
A Randomized Phase II Study of Perioperative mFOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel as Therapy for Resectable Pancreatic Adenocarcinoma
Enrollment Status: Completed
Publish Date: October 19, 2022
Intervention Type: Drug, Procedure
Study Drugs: Fluorouracil, Gemcitabine hydrochloride, Irinotecan hydrochloride, Oxaliplatin, Paclitaxel albumin-stabilized nanoparticle formulation
Study Phase: Phase 2
A Phase Ib/II Study of Cetuximab and Pembrolizumab in Metastatic Colorectal Cancer
A Phase Ib/II Study of Cetuximab and Pembrolizumab in Metastatic Colorectal Cancer
Enrollment Status: Completed
Publish Date: October 06, 2022
Intervention Type: Other, Biological
Study Phase: Phase 1/Phase 2
An Open-Label, Multicenter Phase 1a/2a Trial Investigating the Safety, Tolerability and Antitumor Activity of Multiple Doses of Sym015, a Monoclonal Antibody Mixture Targeting MET, in Patients With Advanced Solid Tumor Malignancies
An Open-Label, Multicenter Phase 1a/2a Trial Investigating the Safety, Tolerability and Antitumor Activity of Multiple Doses of Sym015, a Monoclonal Antibody Mixture Targeting MET, in Patients With Advanced Solid Tumor Malignancies
Enrollment Status: Completed
Publish Date: June 22, 2022
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
View 14 Less Clinical Trials

37 Total Publications

Incorporating Circulating Tumor DNA Testing Into Clinical Trials: A Position Paper by the National Cancer Institute GI Oncology Circulating Tumor DNA Working Group.
Incorporating Circulating Tumor DNA Testing Into Clinical Trials: A Position Paper by the National Cancer Institute GI Oncology Circulating Tumor DNA Working Group.
Journal: JCO precision oncology
Published: March 06, 2025
View All 37 Publications
Similar Doctors
Distinguished in Hairy Cell Leukemia (HCL)
Dr. Nick C. Leasure
Hematology Oncology | Hematology | Oncology
Distinguished in Hairy Cell Leukemia (HCL)
Dr. Nick C. Leasure
Hematology Oncology | Hematology | Oncology

Reading Hospital

420 S 5th Ave, Outpatient Services, 
West Reading, PA 
 (47.9 miles away)
484-628-8103
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Nick Leasure is a Hematologist Oncology specialist and a Hematologist in West Reading, Pennsylvania. Dr. Leasure is rated as a Distinguished provider by MediFind in the treatment of Hairy Cell Leukemia (HCL). His top areas of expertise are Paget Disease of the Breast, Breast Cancer, Hairy Cell Leukemia (HCL), and Reticuloendotheliosis.

Distinguished in Hairy Cell Leukemia (HCL)
Dr. John D. Sprandio
Hematology Oncology | Hematology | Oncology
Distinguished in Hairy Cell Leukemia (HCL)
Dr. John D. Sprandio
Hematology Oncology | Hematology | Oncology

Consultants In Medical Oncology And Hematology PC

30 Lawrence Rd, Suite 201, 
Broomall, PA 
 (8.0 miles away)
610-492-5900
Languages Spoken:
English
See accepted insurances

John Sprandio is a Hematologist Oncology specialist and a Hematologist in Broomall, Pennsylvania. Dr. Sprandio is rated as a Distinguished provider by MediFind in the treatment of Hairy Cell Leukemia (HCL). His top areas of expertise are Hairy Cell Leukemia (HCL), Liver Cancer, Familial Colorectal Cancer, and Paget Disease of the Breast.

Advanced in Hairy Cell Leukemia (HCL)
Dr. Thomas R. Blom
Hematology | Oncology
Advanced in Hairy Cell Leukemia (HCL)
Dr. Thomas R. Blom
Hematology | Oncology

Princeton Medical Group Oncology And Hematology - Plainsboro Office

3 Liberty Street, Plainsboro Village Center, 
Plainsboro, NJ 
 (41.1 miles away)
609-924-9300
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Thomas Blom is a Hematologist and an Oncologist in Plainsboro, New Jersey. Dr. Blom is rated as a Distinguished provider by MediFind in the treatment of Hairy Cell Leukemia (HCL). His top areas of expertise are Non-Hodgkin Lymphoma, Multiple Myeloma, Inflammatory Breast Cancer, and Polycythemia Vera. Dr. Blom is currently accepting new patients.

VIEW MORE HAIRY CELL LEUKEMIA (HCL) DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Eads's expertise for a condition
ConditionClose
  • Elite
  • Neuroendocrine Tumor
    Dr. Eads is
    Elite
    . Learn about Neuroendocrine Tumor.
    See more Neuroendocrine Tumor experts
  • Distinguished
  • Colorectal Cancer
    Dr. Eads is
    Distinguished
    . Learn about Colorectal Cancer.
    See more Colorectal Cancer experts
  • Familial Colorectal Cancer
    Dr. Eads is
    Distinguished
    . Learn about Familial Colorectal Cancer.
    See more Familial Colorectal Cancer experts
  • Gastrointestinal Stromal Tumor
    Dr. Eads is
    Distinguished
    . Learn about Gastrointestinal Stromal Tumor.
    See more Gastrointestinal Stromal Tumor experts
  • Mesenchymoma
    Dr. Eads is
    Distinguished
    . Learn about Mesenchymoma.
    See more Mesenchymoma experts
  • Stomach Cancer
    Dr. Eads is
    Distinguished
    . Learn about Stomach Cancer.
    See more Stomach Cancer experts
  • Undifferentiated Pleomorphic Sarcoma
    Dr. Eads is
    Distinguished
    . Learn about Undifferentiated Pleomorphic Sarcoma.
    See more Undifferentiated Pleomorphic Sarcoma experts
  • Advanced
  • Familial Pancreatic Cancer
    Dr. Eads is
    Advanced
    . Learn about Familial Pancreatic Cancer.
    See more Familial Pancreatic Cancer experts
  • Gallbladder Adenocarcinoma
    Dr. Eads is
    Advanced
    . Learn about Gallbladder Adenocarcinoma.
    See more Gallbladder Adenocarcinoma experts
  • Gallbladder Cancer
    Dr. Eads is
    Advanced
    . Learn about Gallbladder Cancer.
    See more Gallbladder Cancer experts
  • Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET)
    Dr. Eads is
    Advanced
    . Learn about Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET).
    See more Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) experts
  • Glucagonoma
    Dr. Eads is
    Advanced
    . Learn about Glucagonoma.
    See more Glucagonoma experts
  • Lynch Syndrome
    Dr. Eads is
    Advanced
    . Learn about Lynch Syndrome.
    See more Lynch Syndrome experts
View All 11 Advanced Conditions
  • Experienced
  • Acute Myeloblastic Leukemia with Maturation
    Dr. Eads is
    Experienced
    . Learn about Acute Myeloblastic Leukemia with Maturation.
    See more Acute Myeloblastic Leukemia with Maturation experts
  • Acute Myeloblastic Leukemia without Maturation
    Dr. Eads is
    Experienced
    . Learn about Acute Myeloblastic Leukemia without Maturation.
    See more Acute Myeloblastic Leukemia without Maturation experts
  • Acute Myeloid Leukemia (AML)
    Dr. Eads is
    Experienced
    . Learn about Acute Myeloid Leukemia (AML).
    See more Acute Myeloid Leukemia (AML) experts
  • Adrenal Cancer
    Dr. Eads is
    Experienced
    . Learn about Adrenal Cancer.
    See more Adrenal Cancer experts
  • Agranulocytosis
    Dr. Eads is
    Experienced
    . Learn about Agranulocytosis.
    See more Agranulocytosis experts
  • ALK-Positive Non-Small Cell Lung Cancer
    Dr. Eads is
    Experienced
    . Learn about ALK-Positive Non-Small Cell Lung Cancer.
    See more ALK-Positive Non-Small Cell Lung Cancer experts
View All 44 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile
For Patients
  • Our Story
  • How MediFind Works
  • Conditions A-Z
  • Doctor Directory
  • Symptoms Directory
  • Procedures Directory
  • Treatment Directory
  • Drug Directory
  • Infusion Center Finder
  • FAQ
  • Contact Us
For Providers and Practices
  • Claim Your Profile
  • Newsroom
Business Solutions
  • Provider
  • Network Solutions
Additional Resources
  • Consumer Health Data Privacy Policy
  • Privacy Policy
  • Terms of Use
  • Advertising Policy
  • Content Policy
Subscribe to our newsletter

Sign up to stay informed about MediFind and get wellness sent your way.

Close

    By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

    Bullet PinMediFind
    Follow us on
    This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
    © 2026 All Rights Reserved

    Request an Appointment

    If you are experiencing a medical emergency, call 9-1-1.

    MediFind will contact the provider for your appointment request. You’ll receive status updates by email. Your provider or MediFind will reach out to you directly by phone or email to schedule your appointment or request additional information.

    Patient Details

    This information is for the patient who will be seen at the appointment.

      Close

      Returning patient? Use your address on file with the provider.

      Insurance Details

      Please provide information of the primary insurance holder as the practice may require this information to schedule.

      Insurance Provider *
      Insurance ProviderClose

      Appointments Details

      Let’s get more information about your appointment.

              0 / 1000
              0 / 1000
              By pressing the Submit button you are agreeing to MediFind’s Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.